OLANZAPINE TEVA ® 7.5 MG

Country: Իսրայել

language: անգլերեն

source: Ministry of Health

active_ingredient:

OLANZAPINE 7.5 MG

MAH:

SALOMON,LEVIN & ELSTEIN LTD

ATC_code:

N05AH03

pharmaceutical_form:

FILM COATED TABLETS

administration_route:

PER OS

manufactured_by:

TEVA OPERATIONS POLAND SP.ZO.O

therapeutic_group:

OLANZAPINE

therapeutic_indication:

Acute and maintenance treatment of schizophrenia. Olanzapine Teva® is indicated for the management of the manifestations of psychotic disorders. Olanzapine Teva® is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.Prevention of recurrence in Bipolar Disorder: In patients whose manic episode has responded to olanzapine treatment Olanzapine Teva® is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder. The combination of Olanzapine Teva® with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.

authorization_date:

2011-04-01